Potent and selective inhibitory effect of 4-aminoquinoline derivatives on SARS-CoV-2 replication
Innovative Medicines & Omics · 2024
DOI: 10.36922/imo.3442 ↗Kurz gefasst
Fachartikel in der Zeitschrift Innovative Medicines & Omics, 2024. Verfasst von Nicolas Glanzmann und 17 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The global coronavirus disease 2019 (COVID-19) pandemic, caused by the highly infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), had resulted in significant mortality worldwide. In 2020, the World Health Organization started the solidarity clinical trial to assess the efficacy of four proposed therapeutic strategies, including chloroquine (CQ), a 4-aminoquinoline molecule. However, CQ lacks clinical benefit and, therefore, failed to show in vitro anti-SARS-CoV-2 activity in TMPRSS2-expressing cells, such as Calu-3 cell line, which recapitulate human type II pneumocytes. Nevertheless, other 4-aminoquinoline derivatives have shown high affinity toward the SARS-CoV-2 main protease (Mpro). This study aimed to evaluate, in vitro and in silico, the inhibitory potential of nine 4-aminoquinoline derivatives against SARS-CoV-2, building upon the observed antiviral activity of established antimalarial drugs. We assessed the ability of these derivatives to inhibit SARS-CoV-2 (wild type and Omicron variant) replication in Vero E6 and Calu-3 cell lines. In addition, we conducted docking studies to determine the binding affinity and protein-ligand interactions. Notably, these derivatives exhibited potent antiviral activity with low cytotoxicity in Vero E6 and Calu-3 cell models. In silico investigations targeting the Mpro enzyme supported the potential of the derivatives as promising agents in the fight against SARS-CoV-2. Our findings underscore the potential of these 4-aminoquinoline derivatives as robust inhibitors of SARS-CoV-2 and advocate for further research to explore their therapeutic applications, providing valuable insights for future drug development strategies.
Zitieren
APA
Glanzmann, N., Oliveira, T. K. F., Souza, V. C. D., Tucci, A. R., Penna, E. A., Rosa, A. S., Baltazar, M. L. P., Landim, M. J. N., Ferreira, V. N. S., Constantino-Teles, P., Souza, D. D. C., Roxo, S., Freitas, C. S. D., Silva, A. D. P. D. D., Souza, T. M. L., Capriles, P. V. S. Z., Miranda, M. D., & Silva, A. D. D. (2024). Potent and selective inhibitory effect of 4-aminoquinoline derivatives on SARS-CoV-2 replication. Innovative Medicines & Omics. https://doi.org/10.36922/imo.3442
Vancouver
Glanzmann N, Oliveira TKF, Souza VCD, Tucci AR, Penna EA, Rosa AS, et al. Potent and selective inhibitory effect of 4-aminoquinoline derivatives on SARS-CoV-2 replication. Innovative Medicines & Omics. 2024. doi:10.36922/imo.3442
BibTeX
@article{Glanzmann2024,
author = {Glanzmann, Nicolas and Oliveira, Thamara Kelcya F. and Souza, Vinicius Carius de and Tucci, Amanda R. and Penna, Eduarda Alves and Rosa, Alice Santos and Baltazar, Maria Luiza Pereira and Landim, Matheus José Novais and Ferreira, Vivian Neuza S. and Constantino-Teles, Pamella and Souza, Daniel Dias Countinho and Roxo, Sylvia and Freitas, Caroline Souza de and Silva, Aline de Paula Dias da and Souza, Thiago Moreno Lopes and Capriles, Priscila Vanessa S. Zabala and Miranda, Milene Dias and Silva, Adilson D. da},
title = {Potent and selective inhibitory effect of 4-aminoquinoline derivatives on SARS-CoV-2 replication},
journal = {Innovative Medicines & Omics},
year = {2024},
doi = {10.36922/imo.3442}
}
EUVIMED